Rare Disease Products Mostly Approved With Regulatory Flexibility, NORD "Catalog" Finds
This article was originally published in The Pink Sheet Daily
NORD makes the case that FDA should codify unconventional approaches by arguing that the agency already uses them for two-thirds of its orphan approvals.
You may also be interested in...
As rare disease experts become part of orphan drug reviews, stakeholder group says they also should be more accessible to the public.
Stakeholders wonder about impact of placing orphan drug program staff "into review teams" as part of next iteration of user fee program.
FDA tries to MaPP out how and when reviewers can be flexible, moving from 'one-off' to 'boutique' evaluation.